Standard therapy for metastatic melanoma has been evolving over the past several years based on improvements in overall survival provided by the immune checkpoint inhibitors ipilimumab, pembrolizumab and nivolumab, and by agents such as vemurafenib, dabrafenib and trametinib in patients with a tumor BRAF mutation. Here, BRAF is linked to neoplasm.